Thus, silencing FGFR4 leading to activation of the intestinal FXR-FGF15/19 axis allows for advantageous effects of FGF15/19 while avoiding the risk of hypercholesterolemia and hepatic carcinogenesis. This evidence concerns the gene FGFR4 and Hypercholesterolemia.